Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Statement: Crizanlizumab (Adakveo)
July 7, 2023 – SCDAA’s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, 2023, that the conditional marketing authorization for crizanlizumab (Adakveo) be revoked. The EMA stated that this revocation was triggered by the findings of the Novartis STAND multinational clinical trial showing no significant benefit of crizanlizumab over placebo in reducing pain or hospitalizations. Novartis reports that there were no safety problems in STAND. Abstract PB2512 submitted to the 2023 European Hematology Association reports no new safety issues in Novartis’ post-marketing surveillance of over 5,000 patient-treatment-years.
+myBinderRelated Content
-
Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and...Background: In the Dominican Republic,...
-
New Jersey may start a confidential sickle cell trait registryThe New Jersey Legislature is considerin...
-
Blood transfusion for preventing primary and secondary stroke in people with sickle cell diseaseBackground:Sickle cell disease is one of...
-
Bluebird Bio Presents Data From LentiGlobin Gene Therapy TrialBluebird Bio’s investigational gene th...
-
NHLBI Stepping Up Efforts to Apprise SCD Patients of Therapies and TrialsWide interest in a CBS 60 Minutes story ...
-
ASH offers early look at updated SCD guidelines: Experts formulated >50 recommendations on sickle cell diseaseThe American Society of Hemato...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.